GLUT1 biological function and inhibition: research advances

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ferreira LM. Cancer metabolism: the Warburg effect today. Exp. Mol. Pathol. 89(3), 372–380 (2010).
  Medline CASGoogle Scholar
• 2. Abdou AG, Eldien MM, Elsakka D. GLUT-1 expression in cutaneous basal and squamous cell carcinomas. Int. J. Surg. Pathol. 23(6), 447–453 (2015).
  Medline CASGoogle Scholar
• 3. Ancey PB, Contat C, Meylan E. Glucose transporters in cancer – from tumor cells to the tumor microenvironment. FEBS. J. 285(16), 2926–2943 (2018).
  Medline CASGoogle Scholar
• 4. Ma X, Hui Y, Lin L et al. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak. J. Med. Sci. 31(2), 280–284 (2015).
  MedlineGoogle Scholar
• 5. Qamar S, Fatima S, Rehman A et al. Glucose transporter 1 overexpression in oral squamous cell carcinoma. J. Coll. Physicians Surg. Pak. 29(8), 724–727 (2019).
  MedlineGoogle Scholar
• 6. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34(2–3), 121–138 (2013).
  Medline CASGoogle Scholar
• 7. Carruthers A, Dezutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform please stand up. Am. J. Physiol. Endocrinol. Metab. 297(4), E836–848 (2009).
  Medline CASGoogle Scholar
• 8. Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 524(1–3), 199–203 (2002).
  Medline CASGoogle Scholar
• 9. Reckzeh ES, Waldmann H. Development of glucose transporter (GLUT) inhibitors. Eur. J. Org. Chem. 2020(16), 2321–2329 (2020).
  Medline CASGoogle Scholar
• 10. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers. Arch. 447(5), 480–489 (2004).
  Medline CASGoogle Scholar
• 11. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol. Membr. Biol. 18(4), 247–256 (2001).
  Medline CASGoogle Scholar
• 12. Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 5(10), e197 (2008).
  MedlineGoogle Scholar
• 13. Deng D, Xu C, Sun P et al. Crystal structure of the human glucose transporter GLUT1. Nature 510(7503), 121–125 (2014). •• In this paper, the 3D crystal structure of GLUT1 was reported for the first time, and the structure and transport mechanism of GLUT1 were described in detail.
  Medline CASGoogle Scholar
• 14. Graybill C, Van Hoek AN, Desai D et al. Ultrastructure of human erythrocyte GLUT1. Biochemistry 45(26), 8096–8107 (2006).
  Medline CASGoogle Scholar
• 15. Zottola RJ, Cloherty EK, Coderre PE et al. Glucose transporter function is controlled by transporter oligomeric structure. A single, intramolecular disulfide promotes GLUT1 tetramerization. Biochemistry 34(30), 9734–9747 (1995).
  Medline CASGoogle Scholar
• 16. De Zutter JK, Levine KB, Deng D, Carruthers A. Sequence determinants of GLUT1 oligomerization: analysis by homology-scanning mutagenesis. J. Biol. Chem. 288(28), 20734–20744 (2013).
  MedlineGoogle Scholar
• 17. Lloyd KP, Ojelabi OA, De Zutter JK, Carruthers A. Reconciling contradictory findings: glucose transporter 1 (GLUT1) functions as an oligomer of allosteric, alternating access transporters. J. Biol. Chem. 292(51), 21035–21046 (2017).
  Medline CASGoogle Scholar
• 18. Hamill S, Cloherty EK, Carruthers A. The human erythrocyte sugar transporter presents two sugar import sites. Biochemistry 38(51), 16974–16983 (1999).
  Medline CASGoogle Scholar
• 19. Baker GF, Naftalin RJ. Evidence of multiple operational affinities for D-glucose inside the human erythrocyte membrane. Biochim. Biophys. Acta. 550(3), 474–484 (1979).
  Medline CASGoogle Scholar
• 20. Naftalin RJ. Reassessment of models of facilitated transport and cotransport. J. Membr. Biol. 234(2), 75–112 (2010).
  Medline CASGoogle Scholar
• 21. Tian Y, Shen S, Gu L et al. Computer-aided design of glucoside brain-targeted molecules based on 4PYP. J. Mol. Graph. Model 103, 107819 (2020).
  MedlineGoogle Scholar
• 22. Simpson IA, Dwyer D, Malide D et al. The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol-Endoc. M. 295(2), E242–E253 (2008).
  Medline CASGoogle Scholar
• 23. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 5(4), 237–252 (2007).
  Medline CASGoogle Scholar
• 24. Chen C, Pore N, Behrooz A et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276(12), 9519–9525 (2001). • This paper describes the regulatory mechanism of HIF-1 on GLUT1 in detail.
  Medline CASGoogle Scholar
• 25. Weinstein SP, Haber RS. Glucose transport stimulation by thyroid hormone in ARL 15 cells: partial role of increased GLUT1 glucose transporter gene transcription. Thyroid 3(2), 135–142 (1993).
  Medline CASGoogle Scholar
• 26. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64(7), 2627–2633 (2004).
  Medline CASGoogle Scholar
• 27. Cifuentes M, Garcia MA, Arrabal PM et al. Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J. Cell Physiol. 226(6), 1425–1432 (2011).
  Medline CASGoogle Scholar
• 28. Tan VP, Miyamoto S. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy 11(6), 963–964 (2015).
  MedlineGoogle Scholar
• 29. Angira D, Natarajan N, Dedania SR et al. Characterization of P. aeruginosa glucose 6-phosphate isomerase: a functional insight via in-vitro activity study. Curr. Top. Med. Chem. 20(29), 2651–2661 (2020).
  Medline CASGoogle Scholar
• 30. Webb BA, Forouhar F, Szu FE et al. Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations. Nature 523(7558), 111–114 (2015).
  Medline CASGoogle Scholar
• 31. White MR, Garcin ED. D-glyceraldehyde-3-phosphate dehydrogenase structure and function. Sub-Cell. Biochem. 83, 413–453 (2017).
  Medline CASGoogle Scholar
• 32. Fu Q, Yu Z. Phosphoglycerate kinase 1 (PGK1) in cancer: a promising target for diagnosis and therapy. Life Sci. 256, 117863 (2020).
  Medline CASGoogle Scholar
• 33. Sharif F, Rasul A, Ashraf A et al. Phosphoglycerate mutase 1 in cancer: a promising target for diagnosis and therapy. IUBMB Life 71(10), 1418–1427 (2019).
  Medline CASGoogle Scholar
• 34. Counihan JL, Grossman EA, Nomura DK. Cancer metabolism: current understanding and therapies. Chem. Rev. 118(14), 6893–6923 (2018). • This paper describes the regulatory pathway of GLUT1.
  Medline CASGoogle Scholar
• 35. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24(11), 2482–2490 (2018).
  Medline CASGoogle Scholar
• 36. Reckzeh ES, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1–4. Chembiochem 21(1), 45–52 (2020).
  Medline CASGoogle Scholar
• 37. Yin C, Gao B, Yang J, Wu J. Glucose transporter-1 (GLUT-1) expression is associated with tumor size and poor prognosis in locally advanced gastric cancer. Med. Sci. Monit. Basic Res. 26, e920778 (2020).
  MedlineGoogle Scholar
• 38. Zhao M, Zhang Z. Glucose transporter regulation in cancer: a profile and the loops. Crit. Rev. Eukaryot Gene. Expr. 26(3), 223–238 (2016).
  MedlineGoogle Scholar
• 39. Zhou JC, Zhang JJ, Zhang W et al. Expression of GLUT-1 in nasopharyngeal carcinoma and its clinical significance. Eur. Rev. Med. Pharmacol. Sci. 21(21), 4891–4895 (2017).
  MedlineGoogle Scholar
• 40. Zhou L, Li S, Liu L et al. Recombinant methioninase regulates PI3K/Akt/Glut-1 pathway and inhibits aerobic glycolysis to promote apoptosis of gastric cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 40(1), 27–33 (2020).
  MedlineGoogle Scholar
• 41. National Cancer Institute. Cancer Stat Facts 2019. (2020). https://seer.cancer.gov/statfacts/html/corp.html
  Google Scholar
• 42. Rudlowski C, Moser M, Becker AJ et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 66(5), 404–410 (2004).
  Medline CASGoogle Scholar
• 43. Xintaropoulou C, Ward C, Wise A et al. Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. BMC Cancer 18(1), 636 (2018).
  MedlineGoogle Scholar
• 44. Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am. J. Clin. Pathol. 128(2), 245–254 (2007).
  Medline CASGoogle Scholar
• 45. Stower H. Tracing clear cell renal carcinoma evolution. Nat. Med. 24(6), 702 (2018).
  Google Scholar
• 46. Almeida L, Silva R, Cavadas B et al. GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma. Histol Histopathol 32(10), 1029–1040 (2017).
  Medline CASGoogle Scholar
• 47. Amann T, Maegdefrau U, Hartmann A et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am. J. Pathol. 174(4), 1544–1552 (2009).
  Medline CASGoogle Scholar
• 48. Sun HW, Yu XJ, Wu WC et al. GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. PLoS ONE 11(12), e0168907 (2016).
  MedlineGoogle Scholar
• 49. Nishioka T, Oda Y, Seino Y et al. Distribution of the glucose transporters in human brain tumors. Cancer Res. 52(14), 3972–3979 (1992).
  Medline CASGoogle Scholar
• 50. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72(10), 2979–2985 (1993).
  Medline CASGoogle Scholar
• 51. Shen YM, Arbman G, Olsson B, Sun XF. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int. J. Biol. Markers 26(3), 166–172 (2011).
  Medline CASGoogle Scholar
• 52. Sasaki H, Shitara M, Yokota K et al. Overexpression of GLUT1 correlates with Kras mutations in lung carcinomas. Mol. Med. Rep. 5(3), 599–602 (2012).
  Medline CASGoogle Scholar
• 53. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J. Cell Biochem. 113(2), 553–562 (2012).
  Medline CASGoogle Scholar
• 54. Kapoor K, Finer-Moore JS, Pedersen BP et al. Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides. Proc. Natl. Acad. Sci. USA 113(17), 4711–4716 (2016). •• This paper reports the crystal structure of cytochalasin B and GLUT1 protein complex and elucidates the binding site.
  Medline CASGoogle Scholar
• 55. Moreira L, Araujo I, Costa T et al. Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp. Cell. Res. 319(12), 1784–1795 (2013).
  Medline CASGoogle Scholar
• 56. Brito AF, Ribeiro M, Abrantes AM et al. New approach for treatment of primary liver tumors: the role of quercetin. Nutr. Cancer 68(2), 250–266 (2016).
  Medline CASGoogle Scholar
• 57. Azevedo C, Correia-Branco A, Araujo JR, Guimaraes JT, Keating E, Martel F. The chemopreventive effect of the dietary compound kaempferol on the MCF-7 human breast cancer cell line is dependent on inhibition of glucose cellular uptake. Nutr. Cancer 67(3), 504–513 (2015).
  Medline CASGoogle Scholar
• 58. Salas M, Obando P, Ojeda L et al. Resolution of the direct interaction with and inhibition of the human GLUT1 hexose transporter by resveratrol from its effect on glucose accumulation. Am. J. Physiol. Cell Physiol. 305(1), C90–99 (2013).
  Medline CASGoogle Scholar
• 59. Wu H, He L, Shi J et al. Resveratrol inhibits VEGF-induced angiogenesis in human endothelial cells associated with suppression of aerobic glycolysis via modulation of PKM2 nuclear translocation. Clin. Exp. Pharmacol. Physiol. 45(12), 1265–1273 (2018).
  Medline CASGoogle Scholar
• 60. Jung KH, Lee JH, Thien Quach CH et al. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1alpha activation. J. Nucl. Med. 54(12), 2161–2167 (2013).
  Medline CASGoogle Scholar
• 61. Gunnink LK, Alabi OD, Kuiper BD et al. Curcumin directly inhibits the transport activity of GLUT1. Biochimie 125, 179–185 (2016).
  Medline CASGoogle Scholar
• 62. Hu Y, Lou X, Wang R et al. Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line. Open Med. 14, 552–560 (2019).
  CASGoogle Scholar
• 63. Schimmer AD, Thomas MP, Hurren R et al. Identification of Small Molecules that Sensitize Resistant Tumor Cells to Tumor Necrosis Factor-Family Death Receptors. Cancer Res. 66(4), 2367–2375 (2006).
  Medline CASGoogle Scholar
• 64. Wood TE, Dalili S, Simpson CD et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther. 7(11), 3546–3555 (2008).
  Medline CASGoogle Scholar
• 65. Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3(94), 94ra70 (2011).
  Medline CASGoogle Scholar
• 66. Kraus D, Reckenbeil J, Veit N et al. Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation. Cell. Oncol. 41(5), 485–494 (2018).
  CASGoogle Scholar
• 67. Liu Y, Cao Y, Zhang W et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther. 11(8), 1672–1682 (2012).
  Medline CASGoogle Scholar
• 68. Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg. Med. Chem. Lett. 20(7), 2191–2194 (2010).
  Medline CASGoogle Scholar
• 69. Ojelabi OA, Lloyd KP, Simon AH et al. WZB117 (2-fluoro-6-(m-hydroxybenzoyloxy) phenyl m-hydroxybenzoate) inhibits GLUT1-mediated sugar transport by binding reversibly at the exofacial sugar binding site. J. Biol. Chem. 291(52), 26762–26772 (2016).
  Medline CASGoogle Scholar
• 70. Siebeneicher H, Cleve A, Rehwinkel H et al. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876. ChemMedChem 11(20), 2261–2271 (2016). •• This paper describes the development process of the first highly selective GLUT1 inhibitor in detail.
  Medline CASGoogle Scholar
• 71. Siebeneicher H, Bauser M, Buchmann B et al. Identification of novel GLUT inhibitors. Bioorg. Med. Chem. Lett. 26(7), 1732–1737 (2016).
  Medline CASGoogle Scholar
• 72. Ung PM, Song W, Cheng L et al. Inhibitor discovery for the human GLUT1 from homology modeling and virtual screening. ACS Chem. Biol. 11(7), 1908–1916 (2016).
  Medline CASGoogle Scholar
• 73. Reckzeh ES, Karageorgis G, Schwalfenberg M et al. Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth. Cell Chem. Biol. 26(9), 1214–1228 (2019).
  Medline CASGoogle Scholar
• 74. Kang SA, O'neill DJ, Machl AW et al. Discovery of small-molecule selective mTORC1 inhibitors via direct inhibition of glucose transporters. Cell Chem. Biol. 26(9), 1203–1213 (2019).
  Medline CASGoogle Scholar
• 75. Karageorgis G, Reckzeh ES, Ceballos J et al. Chromopynones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3. Nat. Chem. 10(11), 1103–1111 (2018).
  Medline CASGoogle Scholar
• 76. Ceballos J, Schwalfenberg M, Karageorgis G et al. Synthesis of indomorphan pseudo-natural product inhibitors of glucose transporters GLUT-1 and -3. Angew Chem. Int. Ed. Engl. 58(47), 17016–17025 (2019).
  Medline CASGoogle Scholar
• 77. Cuppoletti J, Mayhew E, Jung CY. Cytochalasin B binding to Ehrlich ascites tumor cells and its relationship to glucose carrier. Biochim. Biophys. Acta. 642(2), 392–404 (1981).
  Medline CASGoogle Scholar
• 78. Nelson KM, Dahlin JL, Bisson J et al. The essential medicinal chemistry of curcumin. J. Med. Chem. 60(5), 1620–1637 (2017).
  Medline CASGoogle Scholar
• 79. Unlu A, Nayir E, Dogukan Kalenderoglu M et al. Curcumin (turmeric) and cancer. J. Buon. 21(5), 1050–1060 (2016).
  MedlineGoogle Scholar
• 80. Capodanno D, Angiolillo DJ. Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation 134(20), 1579–1594 (2016).
  Medline CASGoogle Scholar
• 81. Levine LD, Holland TL, Kim K et al. The role of aspirin and inflammation on reproduction: the EAGeR trial. Can. J. Physiol. Pharmacol. 97(3), 187–192 (2019).
  Medline CASGoogle Scholar
• 82. Liu YX, Feng JY, Sun MM et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta. Pharmacol. Sin. 40(1), 122–132 (2019).
  Medline CASGoogle Scholar
• 83. Wang T, Ning K, Lu TX, Hua D. Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer. Oncol. Rep. 37(2), 1059–1065 (2017). •• This paper describes in detail the drug combination of wzb117 and 5-fluorouracil as GLUT1 inhibitor.
  Medline CASGoogle Scholar
• 84. Sawayama H, Ogata Y, Ishimoto T et al. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. Cancer Sci. 110(5), 1705–1714 (2019).
  Medline CASGoogle Scholar